Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (July 2021)
42 slides from Syngene International's investor presentation, July 2021
Slide 1: Investor Presentation
Investor Presentation July 2021 Strictly confidential and privileged
Slide 2: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 4: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 5: Q1 growth driven by steady performance across all divisions
Q1 growth driven by steady performance across all divisions All figures in Rs. Mn unless otherwise specified Operating Highlights Q1 FY22 Financial Highlights • Growth was driven across all its business divisions as the • Revenue from operations increased by 41% year-on-year Company continued to ope
Slide 6: Q1FY22 Financial Performance
Q1FY22 Financial Performance All figures in Rs. Mn unless otherwise specified P&L Summary Q1 FY22 Q1 FY21 YoY Change • Revenue from operations increased by 41% for the quarter compared to the previous year driven by steady performance across all four divisions and against a flat Revenue from operati
Slide 7: Update on COVID-19
Update on COVID-19 Contributing through science Priorities: employee safety & business continuity • Continued to manufacture Remdesivir for distribution in India and other countries under a voluntary license Safety and wellbeing Client projects on agreement with Gilead Inc. of our people schedule •
Slide 8: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 9: Putting science to work: Who we are and what we do
Putting science to work Who we are and what we do ▪ Offering integrated research, development and manufacturing services to take projects from early discovery to commercial supply ▪ Working with clients from around the world to find solutions to their scientific challenges for small and large molecu
Slide 10: Syngene key facts and figures
Syngene key facts and figures All figures are as on March 31, 2021, unless otherwise specified 400+ active clients 15 collaborations 450+ Patents with top 20 pharmaceutical held with clients companies 2 Mn sq. ft. 4700+ talented team of 90% employees of World class infrastructure, scientists in 25-4
Slide 11: The Syngene advantage
The Syngene advantage Integrated service provider offering end-to-end Flexible and varied business models drug discovery, development and manufacturing To meet client requirements services on a single platform International accreditations Experienced in successfully managing large OHSAS 18001, GLP,
Slide 12: Our experience spans multiple industry segments and partnerships with global leaders
Our experience spans multiple industry segments and partnerships with global leaders across the world Clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs) Leading China based crop protection company Global food and beverage company Large Japanese chemical com
Slide 13: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 14: Biocon group and Syngene
Biocon group and Syngene • Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company • Syngene, a subsidiary of Biocon Limited, was established in 1993 as India’s first Contract Research Organization - Company has 25 years plus of unparalleled experience in novel molecu
Slide 15: About us
About us All figures in Rs. Mn unless otherwise specified A Global CRO Quality Focus • Integrated Drug Discovery, Development and • Quality driven organization Manufacturing service provider • Excellent track record of compliance with • Small and large molecules, ADCs, global regulators oligonucleot
Slide 16: Our journey so far
Our journey so far All figures in Rs. Mn unless otherwise specified Foundation Globalization and strategic collaboration Consolidation and growth • Operations started • Expanded into formulations development • Crossed annual turnover of Rs. 20,000 Mn in 2020 • Expansion of R&D Lab • Contract with En
Slide 17: Our Value Creation Model
Our Value Creation Model Assets ▪ Solid foundations based on extensive laboratory infrastructure, technology investments, skilled workforce, strong leadership, and financial strength Services ▪ Deploying asset base to offer integrated services across scientific discovery, development and manufacturi
Slide 18: Strong track record of growth and profitability
Strong track record of growth and profitability All figures in Rs. Mn unless otherwise specified Client Footprint (%) Client Base ▪ Growth driven by increase in sales from existing clients 5% 4% USA and acquisition of new clients 5% Europe FY21 402 ▪ Strategy to extend client relationship over a lon
Slide 19: Multiple levers for growth going ahead
Multiple levers for growth going ahead Expand/Extend Existing Clients Capacity Expansion - High service integration - Consistent investment - Dedicated centers model - FTE services, manufacturing, formulation, biologics, stability Engage New Clients - Tailored service offerings and Client Capacity d
Slide 20: Our divisions
Our divisions Discovery Development Manufacturing Dedicated Services Services Services R&D Centers Engaged in early-stage Engaged in activities from pre- Engaged in the Dedicated R&D facilities for research, from target clinical to clinical trials, manufacturing of small and strategic clients provid
Slide 21: Our collaboration models
Our collaboration models Dedicated R&D Labs FTE FFS Risk-reward • Dedicated scientific and support teams • Pre-defined numbers of scientific • Client collaboration to deliver agreed • Across a portfolio of stage gate- work exclusively on the client’s project personnel from pre-determined services wi
Slide 22: Our dedicated R&D centers exemplify the success of our long-term strategic alliances
Our dedicated R&D centers exemplify the success of our long-term strategic alliances 300,000+ sq. ft. laboratory space 70,000 sq. ft. laboratory space 60,000 sq. ft. laboratory space 3,200 sq. ft. laboratory space Largest R&D Center in Asia for BMS Dedicated R&D Center in India for Exclusive R&D Cen
Slide 23: Our end-to-end platform enables us to be a one-stop-shop
Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules) Discovery Development Manufacturing Chemistry Drug Substance Small Molecules Large Clinical Supplies Molecules Drug Product Biology Integrated Drug Substance – HPAPI An
Slide 24: Discovery Services: From target to a drug candidate
Discovery Services: From target to a drug candidate Candidate Hit to lead Lead optimisation Development selection Candidate Candidate 5 Lead Selection Development Compounds^ Exploratory PK, Tox and Developability Assessment 20 Lead In-Vivo DMPK Profiling, Compounds^ CADD 500 Lead Generation of focus
Slide 25: Development Services
Development Services ▪ Encompass activities across multiple disciplines as a molecule moves from pre- clinical to clinical trials Preclinical Studies Drug ▪ Key activities include: product Dvpt. ▪ Drug substance development (process R&D and optimisation) Drug Substance ▪ Drug product development (pr
Slide 26: Manufacturing Services
Manufacturing Services Small Molecules • State-of-the-art cGMP (Current Good Manufacturing Practices) and GMP(Good Manufacturing Practice) facility to manufacture new chemical entities (NCEs) • Designed to support multi gram to 100s of kgs/ batch of Intermediates and APIs for clinical trials • New g
Slide 27: Backed by extensive world class infrastructure
Backed by extensive world class infrastructure HQ Campus – 90 Acres in Bangalore where most of Syngene’s capabilities are R&D Expansion: Genome housed today Valley, Hyderabad, India commenced operation in Aug 2019 Biologics Expansion: HQ Campus Biologics Manufacturing Plant Scale: Mammalian- ~100-20
Slide 28: Agile and experienced workforce supported by continuous learning
Agile and experienced workforce supported by our commitment to continuous learning ~5,400 strong pool of employees Environment that engages our employees and enables them to grow 24*% female employees vs 16% in FY16 Adapting to the new normal Fostering inclusion and diversity 4700+ scientists delive
Slide 29: Harnessing digitization and automation
Harnessing digitization and automation Generating reliable and retrievable data by using advanced technology platforms. Online management of specifications, Online document storage and Online Training Platform procedures, policies, checklist, manuals, BMR, issuance which tracks learner SMF, TTD, pro
Slide 30: Strategic Sourcing – agility and resilience that makes a difference
Strategic Sourcing – agility and resilience that makes a difference Our dedicated Strategic Sourcing professionals have the expertise and experience to work closely with our global supplier base to ensure timely delivery of supplies for smooth operations of the company, while ensuring strict adheren
Slide 31: Operational excellence is a way of life
Operational excellence is a way of life Black belt Certification • Syngene rolled out Build capability 29 Nos the SQDECC* continuous improvement program Green Belt Certification 188 Nos organization-wide to engage all employees to improve Create culture of excellence operational efficiency (Function
Slide 32: Led by a globally experienced management team
Led by a globally experienced management team Management team Jonathan Hunt Managing Director and Dr. Mahesh Bhalgat Sibaji Biswas Ashu Tandon Beena Govindaraju Chief Executive officer Chief Operating Officer Chief Financial Officer Chief Commercial Officer VP Corporate Affairs Previous AstraZeneca
Slide 33: Advised by visionary Board of Directors
Advised by visionary Board of Directors Member of he Board Vinita Bali Kiran Mazumdar Shaw Jonathan Hunt Dr. Carl Dcicco Professor Catherine Rosenberg Non-Executive Chairperson Managing Director and Chief Independent Director Non-Executive Director Independent Director Executive officer Chairperson
Slide 34: Committed to sustainability
Committed to sustainability Safety is at the heart of everything we do Committed to environmental protection Accredited with ISO 14001:2015 for its effective Accredited with ISO 45001:2018 for its Occupational Health Environment Management System (EMS) and Safety (OH&S) measures of water conserved t
Slide 35: Industry recognition for scientific capability and best practices
We have consistently received industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018 - At Bengaluru • CMO Leadership Award Winner 2020 - under • Dynamic Enterprise of the Year 2016 - Tech Summit, Bengaluru Categories: Capabilities, Compatibility, At the 9th
Slide 36: Proactively managing risks through our robust risk management framework
Proactively managing risks through our robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk across the business. Every risk owner monitors and manages risks relevant to their area of responsibility. 36 Putting Science to Work Refer Ann
Slide 37: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 38: Q1FY22 financial highlights
Q1FY22 financial highlights All figures in Rs. Mn unless otherwise specified Particulars Q1 FY22 Q1 FY21 YoY Change Q4 FY21 QoQ change Revenue from operations 5,945 4,216 41% 6,586 (10%) Other Income 123 153 (20%) 184 (33%) Total Revenue 6,068 4,369 39% 6,770 (10%) Material and Power Costs 2,082 1,0
Slide 39: FY21 financial highlights
FY21 financial highlights All figures in Rs. Mn unless otherwise specified Particulars FY21 FY20 YoY Change Revenue from operations (excl export incentives) 21,802 19,465 12% Balance Sheet Highlights Export incentives 41 654 (94%) Other Income 646 816 (21%) Total Revenue 22,489 20,935 7% As on 31st
Slide 40: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 41: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* NSE Ticker SYNGENE BSE Ticker 539268 1% Promoter & Market Cap (Rs. Mn) 2,33,785 29% Promoter Group % free-float 29% Public Free-float market cap (Rs. Mn) 67,003 Share Outstanding (Mn) 401 ESOP Trust 3M AD
Slide 42: Thank You
THANK YOU For more details www.syngeneintl.com • Visit www.syngeneintl.com • IR Contact: Krishnan G + 91 806 891 9807 investor@syngeneintl.com Putting Science to Work
Syngene International — Investor Presentation (July 2021) on 6ix